KORU Medical Systems, Inc. (KRMD) - 10-K Summary
Business Context and Reporting Period
Company: KORU Medical Systems, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: KORU develops, manufactures, and commercializes large-volume subcutaneous infusion solutions, primarily the FREEDOM Infusion System, for the delivery of immunoglobulin therapies (treating PIDD and CIDP) and other subcutaneous drugs. The company operates in one reportable segment with revenue streams from domestic core, international core, and pharma services/clinical trials.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Net Revenues | $41.1 million | $33.6 million |
| Gross Profit | $25.6 million | $21.3 million |
| Gross Margin | 62.3% | 63.4% |
| Operating Expenses | $28.6 million | $27.8 million |
| Net Loss | $(2.6) million | $(6.1) million |
| Cash and Cash Equivalents | $8.9 million | $9.6 million |
| Inventory | $3.7 million | $2.8 million |
| Debt | $0 (No outstanding borrowings) | $0.3 million (Note payable) |
Liquidity: The company reported $8.9 million in cash and cash equivalents as of December 31, 2025. It maintains a $5 million revolving credit facility and a $5 million term loan facility, both of which had no outstanding balances at year-end. Management expects cash on hand and operating cash flows to meet requirements for at least the next twelve months.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 22.2% to $41.1 million. This was driven by an 11.0% increase in Domestic Core revenue and an 80.0% surge in International Core revenue. Pharma services and clinical trials revenue declined 5.6% due to timing of project milestones.
- Profitability Improvement: Net loss narrowed significantly by 56.5% (from $6.1 million to $2.6 million), primarily due to higher gross profit ($4.3 million increase) partially offset by a slight increase in operating expenses.
- Margin Compression: Gross margin decreased from 63.4% to 62.3%. Management attributed this to higher material costs, tariff-related charges, and a sales mix shift toward international markets, partially offset by higher average selling prices in the U.S.
- Expense Management: Research and Development (R&D) expenses decreased 16.6% to $4.4 million, driven by lower compensation and the absence of prior-year CTO severance costs. Selling, General, and Administrative (SG&A) expenses increased 8.1% due to higher bonuses, commissions, and legal fees.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: KORU aims to strengthen its position in the subcutaneous immunoglobulin (SCIg) market and expand into novel drug therapies. The company is investing in a next-generation pump and consumable system. Management anticipates continued growth in SCIg driven by increasing diagnoses and expanded indications.
Key Risks and Contingencies:
- Supply Chain Concentration: The company relies on a single supplier (Command Medical Products, Inc.) for all consumable subassemblies and approximately 85% of consumable manufacturing. Disruptions in Nicaragua or Miami warehousing could severely impact operations.
- Customer Concentration: Nine distributors accounted for approximately 77% of net revenues in 2025, with one U.S. distributor contributing 29%.
- Regulatory Compliance: Compliance with the EU Medical Device Regulation (MDR) is required by December 2028 to continue selling in the EU. Failure to comply would materially impact revenues.
- Tariffs and Trade: Changes in U.S. tariff policies (including recent Supreme Court rulings and new Section 122 tariffs) create uncertainty regarding import costs and gross margins.
- Capital Needs: While current liquidity is sufficient for the near term, future growth and product development may require additional equity or debt financing.
Investor Verification Checklist
- Supplier Dependency: Verify the stability of the contract manufacturing relationship with Command Medical Products in Nicaragua and the status of alternative sourcing plans.
- EU MDR Compliance: Assess the progress and capital requirements for achieving EU MDR compliance by the December 2028 deadline.
- Customer Concentration: Monitor the purchasing patterns of the top three distributors, which represent over 50% of product revenues.
- Tariff Impact: Evaluate the potential financial impact of new U.S. trade policies and the likelihood of recovering previously paid tariffs via refunds.
- Cash Burn Rate: Review the trajectory of operating cash flows to ensure the $8.9 million cash balance remains sufficient for the stated 12-month runway without dilutive financing.